Fri, 04/06/2021 - 13:50
The Cambridge Independent reports that three pharmaceutical companies have joined the Milner Consortium collaboration. The companies will be partnering with Dr Nicholas Ktistakis, from the Institute's Signalling research programme, researchers from the ALBORADA Drug Discovery Institute, and the MRC Mitochondrial Biology Unit. The project, announced in March 2021, brings together autophagy experts to identify potential targets to treat neurodegenerative disease.
Read the full article online and the Institute news article Autophagy experts collaborate to hunt down potential drug targets to tackle neurodegeneration.
04 June 2021
By Honor Pollard